Humoral Immunity Abnormalities in Advanced Maternal-Age Women With Recurrent Spontaneous Abortion: A Single Center Study
Abstract
To determine the humoral immunity in advanced maternal-age women with recurrent spontaneous abortion (RSA).
Methods A retrospective study was performed between January 2022 and October 2023 in the Department of Reproductive Immunity of Shanghai First Maternity and Infant Hospital. Women with RSA were recruited and multiple autoantibodies were tested. Multivariate logistic regression was performed to compare the associations between different age groups (20 to 34 years old in the low maternal-age group and 35 to 45 years in the advanced maternal-age group) and multiple autoantibodies, while controlling for three confounding factors, including body mass index (BMI), previous history of live birth, and the number of spontaneous abortions. Then, we investigated the differences in the humoral immunity of advanced maternal-age RSA women and low maternal-age RSA women.
Result A total of 4009 women with RSA were covered in the study. Among them, 1158 women were in the advanced maternal-age group and 2851 women were in the low maternal-age group. The prevalence of antiphospholipid syndrome, systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, and undifferentiated connective tissue disease was 15.6% and 14.1%, 0.0% and 0.1%, 0.9% and 0.9%, 0.3% and 0.0%, and 23.7% and 22.6% in the advanced maternal-age group and low maternal-age group, respectively, showing no statistical difference between the two groups. The positive rates of antiphospholipid antibodies (aPLs), antinuclear antibody (ANA), extractable nuclear antigen (ENA) antibody, anti-double stranded DNA (dsDNA) antibody, anti single-stranded DNA (ssDAN) antibody, antibodies against alpha-fodrin (AAA), and thyroid autoimmunity (TAI) were 19.1% and 19.5%, 6.6% and 6.6%, 9.2% and 10.5%, 2.0% and 2.0%, 2.2% and 1.2%, 5.1% and 4.9%, and 17.8% and 16.8%, respectively. No differences were observed between the two groups. 1.6% of the women in the advanced maternal-age group tested positive for lupus anticoagulant (LA), while 2.7% of the women in the low maternal-age group were LA positive, with the differences being statistically significant (odds ratio=0.36, 95% confidence interval: 0.17-0.78). In the 4008 RSA patients, the cumulative cases tested positive for the three antibodies of the aPLs spectrum were 778, of which 520 cases were positive for anti-β2 glycoprotein Ⅰ antibodies (β2GPⅠ Ab)-IgG/IgM, 58 were positive for aCL-IgG/IgM, 73 were positive for LA, 105 were positive for both β2GPⅠ Ab-IgG/IgM and aCL-IgG/IgM, 17 were positive for both β2GPⅠ Ab-IgG/IgM and LA, 2 were positive for both aCL-IgG/IgM and LA, and 3 were positive for all three antibodies.
Conclusion Our study did not find a difference in humoral immunity between RSA women of advanced maternal age and those of low maternal age.
Keywords: Advanced maternal-age, Recurrent spontaneous abortion, Humoral immunity
Full Text:
PDFReferences
QUENBY S, GALLOS I D, DHILLON-SMITH R K, et al. Miscarriage matters: the epidemiological, physical, psychological, and economic costs of early pregnancy loss. Lancet, 2021, 397(10285): 1658–1667. doi: 10. 1016/S0140-6736(21)00682-6.
BENDER ATIK R, CHRISTIANSEN O B, ELSON J, et al. ESHRE guideline: recurrent pregnancy loss: an update in 2022. Hum Reprod Open, 2023, 2023(1): hoad002. doi: 10.1093/hropen/hoad002.
COOMARASAMY A, DHILLON-SMITH R K, PAPADOPOULOU A, et al. Recurrent miscarriage: evidence to accelerate action. Lancet, 2021, 397: 1675–1682. doi: 10.1016/S0140-6736(21)00681-4.
SAMMARITANO L R. Contraception and preconception counseling in women with autoimmune disease. Best Pract Res Clin Obstet Gynaecol, 2020, 64): 11–23. doi: 10.1016/j.bpobgyn.2019.09.003.
Consensus Writing Group of Chinese Experts on the Diagnosis and Treatment of Spontaneous Abortion. Chinese expert consensus on the diagnosis and treatment of spontaneous abortion. Chin J Pract Gynecol Obstetr, 2020, 36(11): 1082–1090. doi: 10.19538/j.fk2020110113. Practice Committee of the American Society for Reproductive M. Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertil Steril, 2012, 98(5): 1103–1111. doi: 10.1016/j.fertnstert. 2012.06.048.
Division of Obstetrics, Society of Obstetrics and Gynecology, Chinese Medical Association. China expert consensus on the diagnosis and treatment of recurrent abortion. China J Obstet Gynecol, 2022, 57(9): 653–667. doi: 10.3760/cma.j.cn112141-20220421-00259.
Te VELDE E R, PEARSON P L. The variability of female reproductive ageing. Hum Reprod Update, 2002, 8(2): 141–154. doi: 10.1093/humupd.
NYBO ANDERSEN A M, WOHLFAHRT J, CHRISTENS P, et al. Maternal age and fetal loss: population based register linkage study. BMJ, 2000, 320(7251): 1708–1712. doi: 10.1136/bmj.320.7251.1708.
MASTENBROEK S, TWISK M, Van der VEEN F, et al. Preimplantation genetic screening: a systematic review and meta-analysis of RCTs. Hum Reprod Update, 2011, 17(4): 454–466. doi: 10.1093/humupd/dmr003.
KANG H J, MELNICK A P, STEWART J D, et al. Preimplantation genetic screening: who benefits? Fertil Steril, 2016, 106(3): 597–602. doi: 10.1016/j.fertnstert.2016.04.027.
SINGH M, WAMBUA S, LEE S I, et al. Autoimmune diseases and adverse pregnancy outcomes: an umbrella review. Lancet, 2023, 402(Suppl 1): S84. doi: 10.1016/S0140-6736(23)02128-1.
避孕杂志, 2020, 40(7): 527–534. doi: 10.3760/cma.j.cn101441-20200419-00226.
Chinese Experts Consensus Group on Application of Immunosuppressants in Recurrent Spontaneous Abortion Complicated with Rheumatic Diseases. Chinese experts consensus on application of immunosuppressants in recurrent spontaneous abortion complicated with rheumatic disease. Chin J Reprod Contracep, 2020, 40(7): 527–534. doi: 10.3760/cma.j.cn101441-20200419-00226.
KWAK-KIM J, SKARIAH A, WU L et al. Humoral and cellular autoimmunity in women with recurrent pregnancy losses and repeated implantation failures: a possible role of vitamin D. Autoimmun Rev, 2016, 15(10): 943–947. doi: 10.1016/j.autrev.2016.07.015.
BARBHAIYA M, ZUILY S, NADEN R et al. 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Ann Rheum Dis, 2023, 82(10): 1258–1270. doi: 10.1136/ard-2023-224609.
Society of Perinatal Medicine, Chinese Medical ssociation. Expert consensus on diagnosis and management of obstetric antiphospholipid syndrome. Chin J Perinatal Med, 2020, 23(8): 517–522. doi: 10.3760/cma. j.cn113903-20200402-00299.
GAO R, ZENG R, QING P, et al. Antiphospholipid antibodies and pregnancy outcome of assisted reproductive treatment: a systematic review and meta-analysis. Am J Reprod Immunol, 2021, 86(4): e13470. doi: 10.1111/aji.13470.
MANUKYAN D, ROSSMANN H, SCHULZ A, et al. Distribution of antiphospholipid antibodies in a large population-based German cohort. Clin Chem Lab Med, 2016, 54(10): 1663–1670. doi: 10.1515/cclm-2016-0014.
BOSSUYT X, De LANGHE E, BORGHI M O, et al. Understanding and interpreting antinuclear antibody tests in systemic rheumatic diseases. Nat Rev Rheumatol, 2020, 16(12): 715–726. doi: 10.1038/s41584-020-00522-w.
LIU T, GUO X, LIAO Y, et al. Correlation between the presence of antinuclear antibodies and recurrent pregnancy loss: a mini review. Front Endocrinol (Lausanne), 2022, 13: 873286. doi: 10.3389/fendo.2022. 873286.
CHEN S, YANG G, WU P, et al. Antinuclear antibodies positivity is a risk factor of recurrent pregnancy loss: a meta-analysis. Semin Arthritis Rheum, 2020, 50(4): 534–543. doi: 10.1016/j.semarthrit.2020.03.016.
TICCONI C, INVERSETTI A, LOGRUOSSO E, et al. Antinuclear antibodies positivity in women in reproductive age: from infertility to adverse obstetrical outcomes--a meta-analysis. J Reprod Immunol, 2023, 155: 103794. doi: 10.1016/j.jri.2022.103794.
RACOUBIAN E, ZUBAID R M, SHAREEF M A, et al. Prevalence of antinuclear antibodies in healthy Lebanese subjects, 2008-2015: a cross-sectional study involving 10, 814 subjects. Rheumatol Int, 2016, 36(9): 1231–1236. doi: 10.1007/s00296-016-3533-0.
Refbacks
- There are currently no refbacks.
